Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

18th Dec 2015 16:15

SHIRE PLC - Director/PDMR Shareholding

SHIRE PLC - Director/PDMR Shareholding

PR Newswire

London, December 18

Director/PDMR Share Dealings

December 18, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) of the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from October 1 to December 31, 2015.

Type of Security (1)Number of Shares/ADSs
Dominic BlakemoreShares137
Olivier BohuonShares163
William BurnsShares156
Dr. Steven GillisADSs53
Dr. David GinsburgADSs49
David KapplerShares144
Susan KilsbyADSs155
Sara MathewADSs60
Anne MintoShares158

(1) One ADS is equal to three Shares.

The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £44.567 per Share and $198.0411 per ADS.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

In addition, for the purposes of the EU Transparency Directive, it is noted that the Company’s Home Member State is the United Kingdom.

Oliver StrawbridgeSenior Assistant Company Secretary

For further information please contact:

Investor Relations
Matthew Osborne[email protected] +1 781 482 9502
Sarah Elton-Farr[email protected]+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com


Related Shares:

Shire
FTSE 100 Latest
Value8,602.92
Change0.00